STAMBP and neoplasm: Treatment of mice with B16F10 tumours with 18.5 MBq of [177Lu]Lu-DOTA-α-MSH-NPs increased the median survival to 25 d versus 21 d for non-targeted [177Lu]Lu-DOTA-NPs, 14 d for non-radioactive NPs, or 16 d for untreated mice.